News
Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC) stock, maintaining a positive outlook on the company’s future.The research firm’s analyst ...
Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website highlighting data on mevrometostat data in ...
On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ: ORIC), maintaining an Overweight stock rating.Trading at $11.49, ORIC has seen analyst targets ranging from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results